Hydroxocobalamin

Summary

Hydroxocobalamin (CHEMBL2103737) is an approved small molecule (ATC B03BA03); indicated across 10 conditions including acne and anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B03BA03 (+2 more)
• Indications: 10 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103737
Name	Hydroxocobalamin
Type	Small molecule
Max phase	4
ATC	B03BA03, B03BA53, V03AB33

Also known as: Alpharedisol, Cobalin-h, Cyanokit, Hepavit, Hidroxocobalamina, Hydroxocobalamin, Hydroxocobalamin acetate, Hydroxocobalamin anhydrous, Hydroxocobalamine, Hydroxocobalaminum anhydrous, Hydroxocobemine, Hydroxomin

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: 5-hydroxytryptamine receptor 3A, Cholecystokinin receptor type A, Alpha-2C adrenergic receptor, Glucocorticoid receptor, 5-hydroxytryptamine receptor 2C, Adenosine receptor A1, Histamine H1 receptor, Delta-type opioid receptor, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Muscarinic acetylcholine receptor M3, Adenosine receptor A3, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 12 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	8.52	AC50	3	nM	CHEMBL_ACT_25174126
ADORA3	5.21	AC50	6100	nM	CHEMBL_ACT_25133935
PDE3A	5.03	AC50	9400	nM	CHEMBL_ACT_25190411

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
acne	4	MONDO:0011438	EFO:0003894
anemia	4	MONDO:0002280	EFO:0004272
poisoning	4	MONDO:0029000	EFO:0008546

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
cataract	3	MONDO:0005129	MONDO:0005129
toxic shock syndrome	2	MONDO:0001881	EFO:0006834
ulcerative colitis	2	MONDO:0005101	EFO:0000729
keratoconus	2	MONDO:0015486	MONDO:0015486
syndromic disease	2	MONDO:0002254	MONDO:0002254
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE4	4
PHASE2	3
PHASE2/PHASE3	2
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02270749	PHASE4	COMPLETED	Vitamin Deficiencies and Suppletion in Morbid Obesity
NCT03372447	PHASE4	COMPLETED	Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia
NCT04054999	PHASE4	COMPLETED	Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
NCT04627181	PHASE4	UNKNOWN	Do Iron And Vitamin B12 Injections Given Together, Improve Hemoglobin In Patients On Hemodialysis?
NCT07163364	PHASE3	NOT_YET_RECRUITING	A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)
NCT05536596	PHASE2/PHASE3	UNKNOWN	Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy
NCT06160219	PHASE2/PHASE3	COMPLETED	Prophylactic Use of Hydroxycobolamin in Vasoplegic Syndrome in Adult Patients Undergoing Cardiopulmonary Bypass
NCT03446599	PHASE2	WITHDRAWN	Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery
NCT03735316	PHASE2	TERMINATED	Vitamin B12a Vasoplegic Syndrome
NCT03783091	PHASE2	COMPLETED	A Trial of Vitamin B12 in Septic Shock
NCT07469189	PHASE1	COMPLETED	A Study on Hydroxocobalamin Given to Healthy Individual to Monitor Symptoms
NCT01201005	Not specified	COMPLETED	B Vitamin Status in Premature and Small for Gestational Age(SGA) Infants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).